

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10750789	
	Filing Date		2004-01-02	
	First Named Inventor	Myers		
	Art Unit	3739		
	Examiner Name	David Shay		
	Attorney Docket Number	32/1198US3		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10750789
Filing Date		2004-01-02
First Named Inventor	Myers	
Art Unit		3739
Examiner Name	David Shay	
Attorney Docket Number		32/1198US3

1	Garner, LF, et al., "Changes in Equivalent and Gradient Refractive Index of the Crystalline Lens with Accommodation," Optom Vis Sci, 1997, 74(2): 114-9, 1 pg	<input type="checkbox"/>
2	Garner, LF, et al., "Changes in Ocular Dimensions and Refraction with Accommodation," Ophthalmic Physiol. Opt., 1997, 17(1): 12-7, 1 pg	<input type="checkbox"/>
3	Helsterkamp, A., et al, "Nanosurgery in Live Cells Using Ultrashort Laser Pulses," Conference 5695: Optical Interactions with Tissue and Cells XVI, Photonics West, undated, 1 pg	<input type="checkbox"/>
4	Kusak, JR., "Progressively More Complex Star Sutures Formed on Primate Lenses During Periods of Development, Growth and Aging Are Related to Accommodation," Abstracts Online, obtained from the internet on 4/19/2006 at: <a href="http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={C8FdF5D...">http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={C8FdF5D...</a> 4/19/06, 1 pg	<input type="checkbox"/>
5	McBrien, NA, et al., "Experimental Myopia in a Diurnal Mammal (Sciurus Carolinesis) with No Accommodative Ability," J. Physiol., 1993, 469:421-41, 1 pg	<input type="checkbox"/>
6	McCourt, ME, et al., "Refractive State, Depth of Focus, and Accommodation of the Eye of the California ground squirrel (Spermophilu beecheyi)" Vision Res., 1984, 24(10):1261-6, 1 pg	<input type="checkbox"/>
7	Prokofeva, GL, et al., "Effects of Low-Intensity Infrared Laser Irradiation on the Eye An Experiemental Study," Vestn Oftalmol, 1996, 112(1):31-32, 1 pg	<input type="checkbox"/>
8	Rafferty, NS, et al., "Comparative Study of Actin Filament Patterns in Lens Epithelial Cells, Are these determined by the mechanisms of accommodation?, Curr Eye Res., 1989, 8:6):569-79, 1 pg	<input type="checkbox"/>
9	Van Alphen, GW, et al., "Elasticity of Tissues Involved in Accomodation," Vision Res., 1991, 31(7-8):1417-38, 1 pg	<input type="checkbox"/>
10	Wang, B., et al., "In-Vivo Animal Studies on Intraocular Nanosurgery With Low-Energy 80 Mhz Near Infrared Femtosecond Laser Pulses," Conference 5695: Optical Interactions with Tissue and Cells XVI, Photonics West, undated, 1 pg	<input type="checkbox"/>
11	Kuszak, et al, "Light Scanning and Electron Micrographs Have Lead to the Following Interpretations of Secondary Fiber Formation," 2004, 16 pgs	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10750789
Filing Date		2004-01-02
First Named Inventor	Myers	
Art Unit	3739	
Examiner Name	David Shay	
Attorney Docket Number	32/1198US3	

12	Lubatschowski, H., et al., "Treatment of Presbyopia by Cutting the Crystalline Lens: A Comparison of FEM Simulation and Ex Vivo Studies," Lazer Zentrum Hannover e.V.	<input type="checkbox"/>
13	"Principles of Ultrafast Laser Surgery Femtosecond Laser Tissue Interaction," Copyright © Center for Ultrafast Optical Sciences, Un. of Michigan, undated, 3 pgs	<input type="checkbox"/>
14	"Presbyopia-Preconditions," Lazer Zentry Hannover e., undated, 11 pgs	<input type="checkbox"/>
15	Interalase Brochure: The Essential Component of Better Vision	<input type="checkbox"/>
16	AVRO, "Statement of the Use of Animals in Ophthalmic and Visual Research," The Association for Research in Vision and Ophthalmology, copyright © 2002, obtained from the Internet on 1/15/2005 at <a href="http://www.avro.org/AboutAvro/anamlst.asp">http://www.avro.org/AboutAvro/anamlst.asp</a> , 3 pgs	<input type="checkbox"/>
17	Figure 4.2 - Optical constants from a "standard eye," undated, 1 pg	<input type="checkbox"/>
18	Picture of an eye obtained from the internet on 3/28/2005 at <a href="http://www.opt.uh.edu/research/aglasser/aao/gonioni.gif">http://www.opt.uh.edu/research/aglasser/aao/gonioni.gif</a> , 1 pg	<input type="checkbox"/>
19	Pictures of eyes, 5 pgs	<input type="checkbox"/>
20	Loesel paper graphs, 2 pgs	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10750789
Filing Date		2004-01-02
First Named Inventor	Myers	
Art Unit		3739
Examiner Name	David Shay	
Attorney Docket Number		32/1198US3

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10750789
Filing Date	2004-01-02
First Named Inventor	Myers
Art Unit	3739
Examiner Name	David Shay
Attorney Docket Number	32/1198US3

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/kirkadamman/	Date (YYYY-MM-DD)	2006-06-21
Name/Print	Kirk A. Damman	Registration Number	42461

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.